NCT02995057

Brief Summary

Hypodermic needles are conventionally used to deliver drugs and vaccines into the muscle of humans and animals. Side effects of these needle injections are pain, bleeding, and anxiety in patients. An alternative drug and vaccine delivery method is the use of hollow microneedles, which are sub-millimeter needle-like structures. Microneedles are pain- and bleeding-free, as they do not reach the nerve-endings and blood capillaries in the skin. As a result, they are better received by patients and do not induce needle anxiety. As the investigators' microneedles are made of gold- or silver-coated, as well as uncoated nickel, the purpose of this study is to observe their biocompatibility and inertness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2015

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2015

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

August 26, 2015

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
1 year until next milestone

First Posted

Study publicly available on registry

December 16, 2016

Completed
Last Updated

December 16, 2016

Status Verified

December 1, 2016

Enrollment Period

4 months

First QC Date

August 26, 2015

Last Update Submit

December 13, 2016

Conditions

Keywords

MicroneedlesBiocompatibilityAllergyMetalNickelContact dermatitis

Outcome Measures

Primary Outcomes (1)

  • Skin reaction as measured by a contact dermatitis classification system

    Allergic patch-test based grading will be done according to the Wilkinson DS et al 1970 reference.

    7 days

Study Arms (1)

Nickel allergic

Participants have proven nickel allergy

Device: Gold- or silver-coated, or uncoated nickel microneedles

Interventions

The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.

Nickel allergic

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

15 subjects will be enrolled in the trial. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be eligible to enroll in the trial.

You may qualify if:

  • Proven nickel allergy

You may not qualify if:

  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of British Columbia

Vancouver, British Columbia, V6T 1Z3, Canada

Location

MeSH Terms

Conditions

HypersensitivityDermatitis, Contact

Condition Hierarchy (Ancestors)

Immune System DiseasesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Eczematous

Study Officials

  • Urs Hafeli, Ph.D.

    Professor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2015

First Posted

December 16, 2016

Study Start

August 1, 2015

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

December 16, 2016

Record last verified: 2016-12

Data Sharing

IPD Sharing
Will not share

Locations